I believe the upside here is tremendous because of the pipeline, and because last year the price fell dramatically on no really bad news, but clearly IMGN 853 required a Phase 3 instead of a Registrational Phase 2. The Phase 3, and other trials are now underway, and I believe that results in a variety of combination trials are looking good. A really good year would have us above highs seen in 2015.
I'm uncertain when more will be heard from Bayer, but their drug which is in a Registrational Phase 2 should have that trial complete later this year. I believe that it could be on the market by third quarter of next year, and IMGN should see both milestones, and ultimately routinely receive royalties on sales.
Gary
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM